EGFR and head and neck cancer: Partnering with other signaling molecules may also underlie such observed functional heterogeneity, as was shown for the AXL - EGFR (Epidermal Growth Factor receptor), which leads to drug resistance in esophageal and Head and Neck cancers [77].